What did @tatianavvizcaino actually say?
Honestly, the transcript here is a mess. The auto-generated captions appear to have completely failed, producing word salad about "Premium Centers," financial advisors, and community investment that has nothing to do with the video topic. Based on the caption and hashtags, the creator was sharing their first-week experience on Mounjaro (tirzepatide) at the starting 2.5mg dose, including how much weight they lost. The actual spoken content in Spanish was not captured accurately by the transcription tool.
So we are working with the stated context: a personal account of week one on tirzepatide 2.5mg, tagged with insulin resistance, fatty liver, and weight loss. That context is what we will fact-check, because the caption gives us the real claim even if the transcript does not.
Does the science back up first-week weight loss on tirzepatide?
Yes, people do lose weight in week one on tirzepatide, but much of it is not fat. The early weeks on GLP-1 and GIP dual agonists like tirzepatide involve significant fluid loss, reduced food intake, and gastrointestinal changes that show up quickly on a scale. Clinical trials confirm real weight loss over time, but week one numbers are not representative of sustained fat loss.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at the highest doses produced average weight loss of around 20.9% over 72 weeks in adults with obesity. The 2.5mg starting dose is explicitly a titration dose, not a therapeutic dose. It was designed to minimize side effects while the body adjusts, not to drive maximum weight reduction. Any weight lost in week one at this dose is almost certainly a combination of water weight, glycogen depletion, and reduced caloric intake from appetite suppression and nausea, not meaningful fat loss.
What did they get right or wrong?
We cannot fairly assess specific claims from this creator because the transcript is unreadable. What we can say is that starting at 2.5mg is the correct, FDA-approved protocol. That part is right. Where personal experience videos like this often go wrong is in framing week-one scale movement as evidence the drug is "working" in a fat-loss sense, which overstates what is happening biologically.
The hashtags reference insulin resistance and fatty liver disease (higado graso), both of which are legitimate therapeutic targets for tirzepatide. Research does support tirzepatide's effects on hepatic fat. The SURMOUNT-NASH trial (Harrison et al., 2024, New England Journal of Medicine) found tirzepatide significantly reduced liver fat and improved NASH resolution compared to placebo. If the creator is using Mounjaro for those conditions, the science supports it as a reasonable clinical choice, though that is a conversation for a prescribing physician, not a TikTok comment section.
What should you actually know about week one on tirzepatide?
The 2.5mg starting dose is intentionally low. It is not where most therapeutic weight loss happens. Most clinical protocols hold patients at 2.5mg for four weeks before increasing to 5mg. Expecting dramatic fat loss in week one at this dose sets unrealistic expectations that can lead people to pressure their providers into faster dose escalation, which increases side effect risk without necessarily improving outcomes.
Common week-one experiences include nausea, reduced appetite, and sometimes loose stools. These are real physiological effects, not placebo. But they also mean the scale can move for reasons unrelated to fat loss. Losing 2-4 pounds in week one on any GLP-1 medication is plausible. Losing 10 pounds of actual fat in week one is not physiologically possible at any dose. If a creator is reporting very large numbers, context matters enormously.
People watching these videos should also know that individual responses to tirzepatide vary widely. Non-responders exist. The drug works best alongside dietary changes. And for conditions like insulin resistance and fatty liver, the mechanism involves more than just eating less. Tirzepatide affects glucose-dependent insulin secretion, gastric emptying, and lipid metabolism through its dual GIP and GLP-1 receptor activity, which is part of why it outperforms semaglutide in head-to-head weight loss comparisons (Frias et al., 2021, New England Journal of Medicine).
Bottom line for viewers
Week one weight loss on Mounjaro 2.5mg is real but mostly water and glycogen. The drug has strong clinical evidence for weight loss, insulin resistance, and fatty liver disease over months, not days. Personal experience videos can be motivating but should not set your expectations for what week one will look like for you. Talk to a licensed provider before starting, adjusting, or comparing your results to someone else's first-week TikTok.